Injectable Tecentriq wins first approval from British regulator

29 August 2023

Swiss oncology giant Roche (ROG: SIX) has broken new ground in the UK, with the first ever approval for a subcutaneous version of its checkpoint blocker Tecentriq (atezolizumab).

The new formulation, which takes around seven minutes to administer, will offer a considerably more patient-friendly option for patients. The current intravenous infusion takes up to an hour to be administered.

Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has provided marketing authorization for the product in all currently-approved indications, including certain types of lung, bladder, breast and liver cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK